This prospective registry is initiated to follow up on the use of Iclusig® in patients with CML or Ph+ ALL in routine practice in Belgium.
Description: Prescribed dose of Iclusig® in milligrams.
Measure: Prescribed dose of Iclusig® in routine practice in Belgium Time: Up to 3 yearsDescription: Includes treatment effectiveness, complete hematologic response, cytogenetic response, major molecular response.
Measure: Overall clinical benefit rate of Iclusig® based on response criteria for CML or Ph+ ALL in Belgium Time: Up to 3 yearsDescription: Costs associated with the treatment of Iclusig®-related adverse events reported during the registry.
Measure: Estimate of additional health care utilization cost Time: Up to 3 yearsOther
There is one SNP
Costs associated with the treatment of Iclusig®-related adverse events reported during the registry.. Inclusion Criteria: - Patient with confirmed diagnosis of: - CML (chronic, accelerated or blast phase) who is resistant or intolerant to dasatinib or nilotinib; and for whom subsequent treatment with imatinib is not clinically appropriate; or who has the T315I mutation. --- T315I ---
- Ph+ ALL who is resistant or intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who has the T315I mutation. --- T315I ---
Inclusion Criteria: - Patient with confirmed diagnosis of: - CML (chronic, accelerated or blast phase) who is resistant or intolerant to dasatinib or nilotinib; and for whom subsequent treatment with imatinib is not clinically appropriate; or who has the T315I mutation. --- T315I ---